Cancer Trials in Cardiff, United Kingdom
Conditions / Cancer / Cardiff, United Kingdom
Research into Cancer spans multiple therapeutic approaches and trial phases.
16 total trials for this combination
Showing top 10 of 16 trials
Trials
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT03818503 | E²-RADIatE: EORTC-ESTRO RADiotherapy InfrAstrucTure for Europe | RECRUITING | — |
| NCT07440290 | DETERMINE Trial Treatment Arm 07: Dabrafenib in Combination With Trametinib in Adult, Paediatric and Teenage/Young Adult Patients With BRAF V600 Mutation-Positive Cancers. | NOT_YET_RECRUITING | PHASE2/PHASE3 |
| NCT05770037 | DETERMINE Trial Treatment Arm 01: Alectinib in Adult, Paediatric and Teenage/Young Adult Patients With ALK Positive Cancers | RECRUITING | PHASE2/PHASE3 |
| NCT06988475 | DETERMINE Trial Treatment Arm 06: Capmatinib in Adult Patients With Cancers Harbouring MET Dysregulations | RECRUITING | PHASE2/PHASE3 |
| NCT04464226 | Study to Continue Treatment With Darolutamide in Patients Who Have Been Participating in Previous Darolutamide Studies Supported by Bayer | ACTIVE_NOT_RECRUITING | — |
| NCT05770102 | DETERMINE Trial Treatment Arm 02: Atezolizumab in Adult, Paediatric and Teenage/Young Adult Patients With Cancers With High Tumour Mutational Burden (TMB) or Microsatellite Instability-high (MSI-high) or Proven Constitutional Mismatch Repair Deficiency (CMMRD) Disposition | RECRUITING | PHASE2/PHASE3 |
| NCT02804815 | Add-Aspirin: A Trial Assessing the Effects of Aspirin on Disease Recurrence and Survival After Primary Therapy in Common Non Metastatic Solid Tumours | ACTIVE_NOT_RECRUITING | PHASE3 |
| NCT05770544 | DETERMINE Trial Treatment Arm 03: Entrectinib in Adult, Paediatric and Teenage/Young Adult Patients With ROS1 Gene Fusion-Positive Cancers. | RECRUITING | PHASE2/PHASE3 |
| NCT04272203 | A Study to Determine Safety, Tolerability, Pharmacokinetics, and Recommended Phase 2 Dose (RP2D) of Intravenous ABBV-184 in Adult Participants With Previously Treated Cancers | TERMINATED | PHASE1 |
| NCT01817257 | Anticoagulation Length in Cancer Associated Thrombosis | TERMINATED | PHASE2 |